145 related articles for article (PubMed ID: 3198133)
41. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
[TBL] [Abstract][Full Text] [Related]
42. Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells.
Qi CF; Nieroda C; De Filippi R; Greiner JW; Correale P; Schlom J; Tsang KY
Immunol Lett; 1995; 47(1-2):15-24. PubMed ID: 8537095
[TBL] [Abstract][Full Text] [Related]
43. ADCC against human erythrocyte target cells: role of the anti-target cell antibodies in determining lymphocyte killer activity.
Nelson DL; Poplack DG; Holiman BJ; Henkart PA
Clin Exp Immunol; 1979 Mar; 35(3):447-53. PubMed ID: 455783
[TBL] [Abstract][Full Text] [Related]
44. Apparent sensitivity of human K lymphocytes to the spatial orientation and organization of target cell-bound antibodies as measured by the efficiency of antibody-dependent cellular cytotoxicity (ADCC).
Christiaansen JE; Burnside SS; Sears DW
J Immunol; 1987 Apr; 138(7):2236-43. PubMed ID: 3549899
[TBL] [Abstract][Full Text] [Related]
45. Monoclonal antibody to a human salivary gland adenocarcinoma cell line: augmentation of antibody-dependent cell-mediated cytotoxicity activity by streptococcal preparation OK-432 in human salivary gland adenocarcinoma-bearing nude mice given the antibody.
Kaji R; Yoshida H; Yanagawa T; Sato M
J Biol Response Mod; 1989 Oct; 8(5):488-500. PubMed ID: 2552025
[TBL] [Abstract][Full Text] [Related]
46. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
47. Effector characteristics of the IgG3 murine monoclonal antibody 113F1.
Weiner LM; Zarou CM; O'Brien J; Ring D
J Biol Response Mod; 1989 Jun; 8(3):227-37. PubMed ID: 2787391
[TBL] [Abstract][Full Text] [Related]
48. Monoclonal antibodies against leucoagglutinin-reactive human T lymphocyte surface components. Two antibodies which inhibit cell-mediated cytotoxicity at a post-binding stage.
Vargas-Cortes M; Hammarström ML; Hammarström S; Hellström U; Perlmann P
Eur J Immunol; 1986 Jul; 16(7):795-801. PubMed ID: 3522246
[TBL] [Abstract][Full Text] [Related]
49. Characterization of the colorectal carcinoma-associated antigen defined by monoclonal antibody D612.
Fernsten PD; Primus FJ; Greiner JW; Simpson JF; Schlom J
Cancer Res; 1991 Feb; 51(3):926-34. PubMed ID: 1988133
[TBL] [Abstract][Full Text] [Related]
50. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
51. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
52. Humoral and cellular responses of colorectal cancer patients treated with monoclonal antibodies and interferon gamma.
Blottiere HM; Douillard JY; Koprowski H; Steplewski Z
Cancer Immunol Immunother; 1990; 32(1):29-37. PubMed ID: 2126982
[TBL] [Abstract][Full Text] [Related]
53. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
[TBL] [Abstract][Full Text] [Related]
54. Optimization of expression conditions for production of anti-colorectal cancer monoclonal antibody CO17-1A in baculovirus-insect cell system.
Park DY; Lee JH; So YK; Kim YK; Ko K; Park SW; Lee YS; Han YS; Ko K
Hybridoma (Larchmt); 2011 Oct; 30(5):419-26. PubMed ID: 22008068
[TBL] [Abstract][Full Text] [Related]
55. Human lymphocyte and monocyte lysis of tumor cells mediated by a mouse/human IgG1 chimeric monoclonal antibody.
Shaw DR; Harrison G; Sun LK; Shearman C; Ghrayeb J; McKinney S; Daddona PE; LoBuglio AF
J Biol Response Mod; 1988 Apr; 7(2):204-11. PubMed ID: 3361351
[TBL] [Abstract][Full Text] [Related]
56. Antibody-dependent cellular cytotoxicity in patients on chronic hemodialysis.
Koch T; Derer S; Staudinger M; Rossen K; Glorius P; Peipp M; Kellner C; Kunzendorf U; Valerius T; Dechant M
Am J Nephrol; 2013; 38(5):379-87. PubMed ID: 24157422
[TBL] [Abstract][Full Text] [Related]
57. Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen.
Shaw DR; Khazaeli MB; Sun LK; Ghrayeb J; Daddona PE; McKinney S; LoBuglio AF
J Immunol; 1987 Jun; 138(12):4534-8. PubMed ID: 3584980
[TBL] [Abstract][Full Text] [Related]
58. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils.
van der Kolk LE; de Haas M; Grillo-López AJ; Baars JW; van Oers MH
Leukemia; 2002 Apr; 16(4):693-9. PubMed ID: 11960351
[TBL] [Abstract][Full Text] [Related]
59. Different types of FCgamma-receptors are involved in anti-Lewis Y antibody induced effector functions in vitro.
Dettke M; Loibner H
Br J Cancer; 2000 Jan; 82(2):441-5. PubMed ID: 10646902
[TBL] [Abstract][Full Text] [Related]
60. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced.
Ragnhammar P; Fagerberg J; Frödin JE; Hjelm AL; Lindemalm C; Magnusson I; Masucci G; Mellstedt H
Int J Cancer; 1993 Mar; 53(5):751-8. PubMed ID: 8449598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
